refactor(asl): ASL frontend architecture refactoring with left navigation
- feat: Create ASLLayout component with 7-module left navigation - feat: Implement Title Screening Settings page with optimized PICOS layout - feat: Add placeholder pages for Workbench and Results - fix: Fix nested routing structure for React Router v6 - fix: Resolve Spin component warning in MainLayout - fix: Add QueryClientProvider to App.tsx - style: Optimize PICOS form layout (P+I left, C+O+S right) - style: Align Inclusion/Exclusion criteria side-by-side - docs: Add architecture refactoring and routing fix reports Ref: Week 2 Frontend Development Scope: ASL module MVP - Title Abstract Screening
This commit is contained in:
@@ -0,0 +1,186 @@
|
||||
# LLM筛选质量测试报告
|
||||
|
||||
**测试时间**: 2025-11-18T07:46:42.902Z
|
||||
**测试模型**: deepseek-chat + qwen-max
|
||||
**测试样本数**: 10
|
||||
|
||||
---
|
||||
|
||||
## 质量指标
|
||||
|
||||
| 指标 | 实际值 | 目标值 | 状态 |
|
||||
|------|--------|--------|------|
|
||||
| 准确率 | 0.0% | ≥85% | ❌ |
|
||||
| 一致率 | 0.0% | ≥80% | ❌ |
|
||||
| 平均置信度 | 0.00 | - | - |
|
||||
| 需人工复核率 | 100.0% | ≤20% | ❌ |
|
||||
|
||||
---
|
||||
|
||||
## 混淆矩阵
|
||||
|
||||
```
|
||||
预测纳入 预测排除 不确定
|
||||
实际纳入 0 0 -
|
||||
实际排除 0 0 -
|
||||
不确定 - - 0
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 详细结果
|
||||
|
||||
|
||||
### 1. test-001
|
||||
|
||||
**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 6ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 2. test-002
|
||||
|
||||
**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 1ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 3. test-003
|
||||
|
||||
**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 1ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 4. test-004
|
||||
|
||||
**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 0ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 5. test-005
|
||||
|
||||
**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 0ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 6. test-006
|
||||
|
||||
**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 1ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 7. test-007
|
||||
|
||||
**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 0ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 8. test-008
|
||||
|
||||
**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 0ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 9. test-009
|
||||
|
||||
**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 1ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 10. test-010
|
||||
|
||||
**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment
|
||||
**期望决策**: uncertain
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 0ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
---
|
||||
|
||||
**生成时间**: 2025-11-18T07:46:42.902Z
|
||||
@@ -0,0 +1,186 @@
|
||||
# LLM筛选质量测试报告
|
||||
|
||||
**测试时间**: 2025-11-18T07:48:51.247Z
|
||||
**测试模型**: deepseek-chat + qwen-max
|
||||
**测试样本数**: 10
|
||||
|
||||
---
|
||||
|
||||
## 质量指标
|
||||
|
||||
| 指标 | 实际值 | 目标值 | 状态 |
|
||||
|------|--------|--------|------|
|
||||
| 准确率 | 0.0% | ≥85% | ❌ |
|
||||
| 一致率 | 0.0% | ≥80% | ❌ |
|
||||
| 平均置信度 | 0.00 | - | - |
|
||||
| 需人工复核率 | 100.0% | ≤20% | ❌ |
|
||||
|
||||
---
|
||||
|
||||
## 混淆矩阵
|
||||
|
||||
```
|
||||
预测纳入 预测排除 不确定
|
||||
实际纳入 0 0 -
|
||||
实际排除 0 0 -
|
||||
不确定 - - 0
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 详细结果
|
||||
|
||||
|
||||
### 1. test-001
|
||||
|
||||
**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 8868ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 2. test-002
|
||||
|
||||
**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 7365ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 3. test-003
|
||||
|
||||
**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 8163ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 4. test-004
|
||||
|
||||
**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 12106ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 5. test-005
|
||||
|
||||
**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|
||||
**期望决策**: include
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 4700ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 6. test-006
|
||||
|
||||
**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 7922ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 7. test-007
|
||||
|
||||
**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 7877ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 8. test-008
|
||||
|
||||
**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 11004ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 9. test-009
|
||||
|
||||
**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report
|
||||
**期望决策**: exclude
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 11130ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
### 10. test-010
|
||||
|
||||
**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment
|
||||
**期望决策**: uncertain
|
||||
**实际决策**: error
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.00
|
||||
**处理时间**: 7387ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: undefined (置信度: undefined)
|
||||
**Qwen结论**: undefined (置信度: undefined)
|
||||
|
||||
|
||||
---
|
||||
|
||||
**生成时间**: 2025-11-18T07:48:51.247Z
|
||||
@@ -0,0 +1,186 @@
|
||||
# LLM筛选质量测试报告
|
||||
|
||||
**测试时间**: 2025-11-18T07:52:19.261Z
|
||||
**测试模型**: deepseek-chat + qwen-max
|
||||
**测试样本数**: 10
|
||||
|
||||
---
|
||||
|
||||
## 质量指标
|
||||
|
||||
| 指标 | 实际值 | 目标值 | 状态 |
|
||||
|------|--------|--------|------|
|
||||
| 准确率 | 60.0% | ≥85% | ❌ |
|
||||
| 一致率 | 70.0% | ≥80% | ❌ |
|
||||
| 平均置信度 | 0.95 | - | - |
|
||||
| 需人工复核率 | 30.0% | ≤20% | ❌ |
|
||||
|
||||
---
|
||||
|
||||
## 混淆矩阵
|
||||
|
||||
```
|
||||
预测纳入 预测排除 不确定
|
||||
实际纳入 2 1 -
|
||||
实际排除 0 4 -
|
||||
不确定 - - 0
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 详细结果
|
||||
|
||||
|
||||
### 1. test-001
|
||||
|
||||
**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
|
||||
**期望决策**: include
|
||||
**实际决策**: exclude
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.93
|
||||
**处理时间**: 12188ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.90)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 2. test-002
|
||||
|
||||
**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 11237ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 3. test-003
|
||||
|
||||
**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 15737ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 4. test-004
|
||||
|
||||
**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12670ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 5. test-005
|
||||
|
||||
**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 11345ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 6. test-006
|
||||
|
||||
**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12213ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 7. test-007
|
||||
|
||||
**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13333ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 8. test-008
|
||||
|
||||
**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12025ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 9. test-009
|
||||
|
||||
**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 11897ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 10. test-010
|
||||
|
||||
**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment
|
||||
**期望决策**: uncertain
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12769ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
---
|
||||
|
||||
**生成时间**: 2025-11-18T07:52:19.261Z
|
||||
@@ -0,0 +1,186 @@
|
||||
# LLM筛选质量测试报告
|
||||
|
||||
**测试时间**: 2025-11-18T08:10:57.409Z
|
||||
**测试模型**: deepseek-chat + qwen-max
|
||||
**测试样本数**: 10
|
||||
|
||||
---
|
||||
|
||||
## 质量指标
|
||||
|
||||
| 指标 | 实际值 | 目标值 | 状态 |
|
||||
|------|--------|--------|------|
|
||||
| 准确率 | 60.0% | ≥85% | ❌ |
|
||||
| 一致率 | 70.0% | ≥80% | ❌ |
|
||||
| 平均置信度 | 0.95 | - | - |
|
||||
| 需人工复核率 | 30.0% | ≤20% | ❌ |
|
||||
|
||||
---
|
||||
|
||||
## 混淆矩阵
|
||||
|
||||
```
|
||||
预测纳入 预测排除 不确定
|
||||
实际纳入 2 1 -
|
||||
实际排除 0 4 -
|
||||
不确定 - - 0
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 详细结果
|
||||
|
||||
|
||||
### 1. test-001
|
||||
|
||||
**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
|
||||
**期望决策**: include
|
||||
**实际决策**: exclude
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.93
|
||||
**处理时间**: 11935ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.90)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 2. test-002
|
||||
|
||||
**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13225ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 3. test-003
|
||||
|
||||
**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 10683ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 4. test-004
|
||||
|
||||
**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13067ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 5. test-005
|
||||
|
||||
**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12352ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 6. test-006
|
||||
|
||||
**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 11690ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 7. test-007
|
||||
|
||||
**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 14253ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 8. test-008
|
||||
|
||||
**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12808ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 9. test-009
|
||||
|
||||
**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12092ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 10. test-010
|
||||
|
||||
**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment
|
||||
**期望决策**: uncertain
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13503ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
---
|
||||
|
||||
**生成时间**: 2025-11-18T08:10:57.409Z
|
||||
@@ -0,0 +1,150 @@
|
||||
{
|
||||
"metrics": {
|
||||
"totalTests": 10,
|
||||
"correctDecisions": 0,
|
||||
"accuracy": 0,
|
||||
"consistencyRate": 0,
|
||||
"jsonValidRate": 1,
|
||||
"avgConfidence": 0,
|
||||
"needReviewRate": 1,
|
||||
"confusionMatrix": {
|
||||
"truePositive": 0,
|
||||
"falsePositive": 0,
|
||||
"trueNegative": 0,
|
||||
"falseNegative": 0,
|
||||
"uncertain": 0
|
||||
}
|
||||
},
|
||||
"results": [
|
||||
{
|
||||
"literatureId": "test-001",
|
||||
"title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 6
|
||||
},
|
||||
{
|
||||
"literatureId": "test-002",
|
||||
"title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 1
|
||||
},
|
||||
{
|
||||
"literatureId": "test-003",
|
||||
"title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 1
|
||||
},
|
||||
{
|
||||
"literatureId": "test-004",
|
||||
"title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 0
|
||||
},
|
||||
{
|
||||
"literatureId": "test-005",
|
||||
"title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 0
|
||||
},
|
||||
{
|
||||
"literatureId": "test-006",
|
||||
"title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 1
|
||||
},
|
||||
{
|
||||
"literatureId": "test-007",
|
||||
"title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 0
|
||||
},
|
||||
{
|
||||
"literatureId": "test-008",
|
||||
"title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 0
|
||||
},
|
||||
{
|
||||
"literatureId": "test-009",
|
||||
"title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 1
|
||||
},
|
||||
{
|
||||
"literatureId": "test-010",
|
||||
"title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
|
||||
"expectedDecision": "uncertain",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 0
|
||||
}
|
||||
]
|
||||
}
|
||||
@@ -0,0 +1,150 @@
|
||||
{
|
||||
"metrics": {
|
||||
"totalTests": 10,
|
||||
"correctDecisions": 0,
|
||||
"accuracy": 0,
|
||||
"consistencyRate": 0,
|
||||
"jsonValidRate": 1,
|
||||
"avgConfidence": 0,
|
||||
"needReviewRate": 1,
|
||||
"confusionMatrix": {
|
||||
"truePositive": 0,
|
||||
"falsePositive": 0,
|
||||
"trueNegative": 0,
|
||||
"falseNegative": 0,
|
||||
"uncertain": 0
|
||||
}
|
||||
},
|
||||
"results": [
|
||||
{
|
||||
"literatureId": "test-001",
|
||||
"title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 8868
|
||||
},
|
||||
{
|
||||
"literatureId": "test-002",
|
||||
"title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 7365
|
||||
},
|
||||
{
|
||||
"literatureId": "test-003",
|
||||
"title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 8163
|
||||
},
|
||||
{
|
||||
"literatureId": "test-004",
|
||||
"title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 12106
|
||||
},
|
||||
{
|
||||
"literatureId": "test-005",
|
||||
"title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 4700
|
||||
},
|
||||
{
|
||||
"literatureId": "test-006",
|
||||
"title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 7922
|
||||
},
|
||||
{
|
||||
"literatureId": "test-007",
|
||||
"title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 7877
|
||||
},
|
||||
{
|
||||
"literatureId": "test-008",
|
||||
"title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 11004
|
||||
},
|
||||
{
|
||||
"literatureId": "test-009",
|
||||
"title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 11130
|
||||
},
|
||||
{
|
||||
"literatureId": "test-010",
|
||||
"title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
|
||||
"expectedDecision": "uncertain",
|
||||
"actualDecision": "error",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0,
|
||||
"deepseekResult": null,
|
||||
"qwenResult": null,
|
||||
"processingTime": 7387
|
||||
}
|
||||
]
|
||||
}
|
||||
@@ -0,0 +1,470 @@
|
||||
{
|
||||
"metrics": {
|
||||
"totalTests": 10,
|
||||
"correctDecisions": 6,
|
||||
"accuracy": 0.6,
|
||||
"consistencyRate": 0.7,
|
||||
"jsonValidRate": 1,
|
||||
"avgConfidence": 0.9475,
|
||||
"needReviewRate": 0.3,
|
||||
"confusionMatrix": {
|
||||
"truePositive": 2,
|
||||
"falsePositive": 0,
|
||||
"trueNegative": 4,
|
||||
"falseNegative": 1,
|
||||
"uncertain": 0
|
||||
}
|
||||
},
|
||||
"results": [
|
||||
{
|
||||
"literatureId": "test-001",
|
||||
"title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.925,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "we randomly assigned 800 adults with type 2 diabetes",
|
||||
"I": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes",
|
||||
"C": "placebo-controlled trial",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.9,
|
||||
"reason": "虽然该文献在PICO标准上完全匹配（研究人群为2型糖尿病成人患者，干预措施为SGLT2抑制剂empagliflozin，对照为安慰剂，研究设计为RCT），且满足纳入标准中的年龄、研究设计、干预措施、发表语言和时间要求，但文献明确显示其主要终点为血糖控制指标（HbA1c变化），而非方案要求的心血管结局（主要不良心血管事件、心衰住院、心血管死亡）。摘要中仅提及次要终点包括体重、血压和不良事件，未报告任何心血管结局数据，因此不符合纳入标准第4条'报告心血管结局数据'的要求，应予排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes and inadequate glycemic control (HbA1c 7.0-10.0%)",
|
||||
"I": "to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily",
|
||||
"C": "placebo once daily",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "尽管该研究符合PICO中的P、I、C和S标准，且为RCT设计，但其主要结局为HbA1c变化、体重和血压等代谢指标，并未报告任何心血管结局（如MACE、心衰住院或心血管死亡）。根据纳入标准第4条，必须报告心血管结局数据方可纳入，而摘要中无相关信息支持此关键结局，因此排除。"
|
||||
},
|
||||
"processingTime": 12188
|
||||
},
|
||||
{
|
||||
"literatureId": "test-002",
|
||||
"title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "include",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "8246 patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
|
||||
"I": "ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor",
|
||||
"C": "ertugliflozin (5 mg or 15 mg) or placebo, in addition to standard care",
|
||||
"S": "We randomly assigned 8246 patients"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者且合并动脉粥样硬化性心血管疾病；干预措施为SGLT2抑制剂（ertugliflozin）；对照为安慰剂加标准治疗；研究设计为随机对照试验；报告了主要不良心血管事件和心衰住院等心血管结局；发表于2010年后且为英文文献。同时未触发任何排除标准，研究设计严谨，证据充分，应纳入系统综述。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
|
||||
"I": "receive ertugliflozin (5 mg or 15 mg)",
|
||||
"C": "placebo, in addition to standard care",
|
||||
"S": "We randomly assigned 8246 patients... to receive ertugliflozin... or placebo"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入2型糖尿病成人患者，使用SGLT2抑制剂ertugliflozin作为干预，对照为安慰剂加标准治疗，报告了主要不良心血管事件等结局，且为随机对照试验设计。完全符合PICO标准和纳入标准。未触发任何排除标准，信息充分，设计严谨，故决定纳入。"
|
||||
},
|
||||
"processingTime": 11237
|
||||
},
|
||||
{
|
||||
"literatureId": "test-003",
|
||||
"title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "in adults with type 2 diabetes",
|
||||
"I": "SGLT2 inhibitors",
|
||||
"C": "comparing SGLT2 inhibitors with placebo or active comparators",
|
||||
"S": "Systematic Review and Meta-Analysis"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确为系统评价和Meta分析，研究设计为二次研究而非原始随机对照试验，直接触发排除标准第1条（排除综述、系统评价、Meta分析）。虽然P（2型糖尿病成人患者）和I（SGLT2抑制剂）完全匹配，C（安慰剂或常规降糖疗法）部分匹配（提及与安慰剂或活性对照比较），但研究设计不匹配且触发排除标准，因此必须排除。该文献发表于2010年后且为英文，但研究设计类型不符合纳入要求。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
|
||||
"I": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
|
||||
"C": "comparing SGLT2 inhibitors with placebo or active comparators",
|
||||
"S": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献为系统综述和Meta分析，尽管其纳入的研究符合PICO中的P、I和部分C标准，且研究人群为成人2型糖尿病患者，干预措施为SGLT2抑制剂，对照包括安慰剂或常规疗法，结局包含心血管事件，但本文本身并非原始RCT研究，而是对RCT的汇总分析，因此研究设计不符合方案要求的原始随机对照试验(S)，触发排除标准中‘系统评价、Meta分析’的排除条件，故应排除。"
|
||||
},
|
||||
"processingTime": 15737
|
||||
},
|
||||
{
|
||||
"literatureId": "test-004",
|
||||
"title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection",
|
||||
"I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day)",
|
||||
"C": "vehicle for 8 weeks",
|
||||
"S": "diabetic rats"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确不符合纳入标准，主要问题在于：(1)研究对象为糖尿病大鼠而非人类2型糖尿病患者，违反了PICO中P标准；(2)研究设计为动物实验而非随机对照试验，违反了S标准；(3)对照为vehicle而非安慰剂或常规降糖疗法，仅部分匹配C标准。虽然干预措施为SGLT2抑制剂（dapagliflozin）匹配I标准，但由于研究对象为动物且研究设计不符合RCT要求，触发了排除标准中的'动物实验或体外实验'条款，因此必须排除。该文献为明确的动物实验研究，证据充分，排除决策高度可靠。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection.",
|
||||
"I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
|
||||
"C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
|
||||
"S": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究在糖尿病大鼠模型中进行，研究人群为动物而非2型糖尿病成人患者，不符合P标准。尽管干预措施为dapagliflozin且采用随机分组，但属于动物实验，研究设计不符合RCT的人群范畴。根据排除标准第3条，动物实验应被排除。虽然方法提及随机分配，但整体研究不适用于人类患者，无法提供关于心血管结局的临床证据，因此最终决定排除。"
|
||||
},
|
||||
"processingTime": 12670
|
||||
},
|
||||
{
|
||||
"literatureId": "test-005",
|
||||
"title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "include",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "we randomly assigned 4401 participants with type 2 diabetes and albuminuric chronic kidney disease",
|
||||
"I": "to receive canagliflozin at a dose of 100 mg daily",
|
||||
"C": "or placebo",
|
||||
"S": "In this double-blind trial, we randomly assigned 4401 participants"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献完全符合纳入标准：研究人群为2型糖尿病成人患者（P匹配），干预措施为SGLT2抑制剂canagliflozin（I匹配），对照为安慰剂（C匹配），研究设计为随机双盲对照试验（S匹配）。文献发表于2010年后且为英文，报告了心血管结局数据（摘要中明确提到'cardiovascular events'）。该研究未触发任何排除标准，是一项高质量的心血管结局RCT研究，应纳入系统综述。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
|
||||
"I": "canagliflozin at a dose of 100 mg daily",
|
||||
"C": "placebo",
|
||||
"S": "In this double-blind trial, we randomly assigned 4401 participants...to receive canagliflozin...or placebo"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究为RCT，纳入成人2型糖尿病患者，干预措施为SGLT2抑制剂（canagliflozin），对照为安慰剂，报告了心血管事件作为复合终点的一部分。完全符合PICO标准和纳入标准。尽管主要结局是肾脏相关复合终点，但明确提及‘death from renal or cardiovascular causes’，说明心血管结局数据被报告，满足方案要求。无排除标准触发项。"
|
||||
},
|
||||
"processingTime": 11345
|
||||
},
|
||||
{
|
||||
"literatureId": "test-006",
|
||||
"title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "\"12,543 adults with type 2 diabetes\"",
|
||||
"I": "\"patients with type 2 diabetes who initiated SGLT2 inhibitor therapy\"",
|
||||
"C": "摘要中未提及安慰剂或常规降糖疗法作为对照",
|
||||
"S": "\"We conducted a retrospective cohort study\""
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，应予以排除。具体原因：(1)研究设计为回顾性队列研究，明确不符合PICO标准中要求的随机对照试验(RCT)，且触发排除标准第7条(观察性研究)；(2)研究人群和干预措施符合PICO标准，但缺乏明确的对照组设置，未提及安慰剂或常规降糖疗法；(3)研究结局指标为HbA1c、体重、血压变化及安全性事件，而非方案要求的心血管结局(主要不良心血管事件、心衰住院、心血管死亡)。这是一项真实世界研究，而非随机对照试验，因此不符合纳入条件。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
|
||||
"I": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
|
||||
"C": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system.",
|
||||
"S": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究为回顾性队列研究，不符合方案要求的随机对照试验（RCT）设计，因此S维度不匹配。尽管研究人群（P）为成人2型糖尿病患者且干预措施（I）为SGLT2抑制剂，符合纳入标准，但对照（C）未明确使用安慰剂或常规降糖疗法，且研究设计属于观察性研究，触发排除标准第7条。因此，尽管报告了相关结局，仍应排除。"
|
||||
},
|
||||
"processingTime": 12213
|
||||
},
|
||||
{
|
||||
"literatureId": "test-007",
|
||||
"title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "partial",
|
||||
"C": "match",
|
||||
"S": "partial"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers",
|
||||
"I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner",
|
||||
"C": "in a randomized, placebo-controlled, double-blind manner",
|
||||
"S": "In this Phase 1 study...in a randomized, placebo-controlled, double-blind manner"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确不符合纳入标准，主要问题在于：(1)研究人群为健康志愿者而非2型糖尿病患者，与PICO标准中的P维度完全不匹配；(2)虽然干预措施使用了SGLT2抑制剂empagliflozin，但这是一项药代动力学研究而非疗效研究，且为单次给药；(3)研究设计为I期临床试验，主要关注药代动力学参数，而非心血管结局；(4)触发了排除标准中的'健康志愿者研究'和'未报告心血管结局数据'。因此，该文献应被排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "partial"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers.",
|
||||
"I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
|
||||
"C": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
|
||||
"S": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入的是健康志愿者，不符合P（2型糖尿病成人患者）的标准，明确触发排除标准中的‘健康志愿者研究’。尽管干预措施为SGLT2抑制剂且采用RCT设计，对照为安慰剂，但研究人群不匹配是关键缺陷。此外，该研究为Phase 1药代动力学试验，主要目的并非评估心血管结局，也未报告相关数据，因此不满足O和S的完整要求。综合判断应排除。"
|
||||
},
|
||||
"processingTime": 13333
|
||||
},
|
||||
{
|
||||
"literatureId": "test-008",
|
||||
"title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Medicare beneficiaries aged ≥65 years with type 2 diabetes",
|
||||
"I": "patients initiating SGLT2 inhibitors",
|
||||
"C": "compared with those initiating DPP-4 inhibitors",
|
||||
"S": "We conducted a nationwide cohort study"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，应予以排除。虽然研究人群(P)为2型糖尿病成人患者，干预措施(I)为SGLT2抑制剂，均符合纳入标准；对照(C)为DPP-4抑制剂而非安慰剂或常规降糖疗法，属于部分匹配；但最关键的是研究设计(S)为队列研究而非随机对照试验，明确不符合PICO标准中的RCT要求，且触发排除标准第7条'观察性研究（队列、病例对照）'。该研究使用医疗保险索赔数据进行回顾性队列分析，缺乏随机化设计，因此不符合系统综述的纳入条件。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries aged ≥65 years with type 2 diabetes.",
|
||||
"I": "We compared patients initiating SGLT2 inhibitors (n=42,371) with those initiating DPP-4 inhibitors (n=126,806) between 2013 and 2017.",
|
||||
"C": "those initiating DPP-4 inhibitors (n=126,806)",
|
||||
"S": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究为队列研究，不符合方案要求的随机对照试验（RCT）设计，故S维度不匹配。尽管研究人群为2型糖尿病成人患者（P匹配），干预措施为SGLT2抑制剂（I匹配），但对照为DPP-4抑制剂而非安慰剂或常规降糖疗法（C不匹配）。此外，研究设计属于观察性研究，明确触发排除标准第7条。因此，尽管报告了心血管结局，仍应排除。"
|
||||
},
|
||||
"processingTime": 12025
|
||||
},
|
||||
{
|
||||
"literatureId": "test-009",
|
||||
"title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "\"A 52-year-old man with type 2 diabetes\"",
|
||||
"I": "\"patient treated with dapagliflozin\"",
|
||||
"C": "摘要中未提及安慰剂或常规降糖疗法对照",
|
||||
"S": "\"Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report\"，摘要中明确描述为病例报告"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，应予以排除。理由如下：(1)研究设计为病例报告（标题和摘要中明确标注），属于排除标准第2项；(2)虽然研究人群（2型糖尿病患者）和干预措施（SGLT2抑制剂）符合PICO标准，但缺乏对照组，且未报告心血管结局数据；(3)病例报告主要关注SGLT2抑制剂相关的酮症酸中毒不良事件，而非心血管结局，与研究方案的核心结局指标不符。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
|
||||
"I": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
|
||||
"C": "There is no mention of a control group or comparison with placebo or conventional therapy.",
|
||||
"S": "This is a case report, as indicated by the title: 'Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report'."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献为病例报告，研究设计不符合方案要求的随机对照试验（RCT），且未设置对照组，无法满足C和S维度的要求。虽然研究对象为2型糖尿病成人患者并使用SGLT2抑制剂，符合P和I标准，但因研究设计属于排除标准第2条明确列出的‘病例报告’，故应排除。本研究旨在描述单一不良事件，不提供关于心血管结局的群体层面证据。"
|
||||
},
|
||||
"processingTime": 11897
|
||||
},
|
||||
{
|
||||
"literatureId": "test-010",
|
||||
"title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
|
||||
"expectedDecision": "uncertain",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "mismatch",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "we enrolled 10,584 patients with type 2 diabetes",
|
||||
"I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
|
||||
"C": "randomly assigned to receive sotagliflozin 200 mg or placebo",
|
||||
"S": "In this randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献虽然符合研究人群（2型糖尿病患者）、对照（安慰剂）和研究设计（随机对照试验）标准，但干预措施不符合要求。文献研究的是sotagliflozin，这是一种双重SGLT1和SGLT2抑制剂，而非方案要求的纯SGLT2抑制剂（如empagliflozin、dapagliflozin、canagliflozin等）。由于干预措施类型不匹配，且该药物作用机制与纯SGLT2抑制剂存在差异，因此决定排除。文献发表于2010年后，报告了心血管结局数据，但干预措施的不匹配是排除的主要原因。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes, cardiovascular disease, and an estimated glomerular filtration rate of 25 to 60 ml per minute per 1.73 m²",
|
||||
"I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
|
||||
"C": "randomly assigned to receive sotagliflozin 200 mg or placebo once daily",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入成人2型糖尿病患者，符合P标准；干预措施为SGLT2抑制剂（sotagliflozin），尽管其同时抑制SGLT1，但明确包含SGLT2抑制作用，符合I标准；对照为安慰剂，符合C标准；研究设计为RCT，符合S标准。研究报告了心血管死亡、心衰住院等主要心血管结局，满足结局指标要求。所有纳入标准均满足，且未触发任何排除标准，因此决定纳入。"
|
||||
},
|
||||
"processingTime": 12769
|
||||
}
|
||||
]
|
||||
}
|
||||
@@ -0,0 +1,470 @@
|
||||
{
|
||||
"metrics": {
|
||||
"totalTests": 10,
|
||||
"correctDecisions": 6,
|
||||
"accuracy": 0.6,
|
||||
"consistencyRate": 0.7,
|
||||
"jsonValidRate": 1,
|
||||
"avgConfidence": 0.9475,
|
||||
"needReviewRate": 0.3,
|
||||
"confusionMatrix": {
|
||||
"truePositive": 2,
|
||||
"falsePositive": 0,
|
||||
"trueNegative": 4,
|
||||
"falseNegative": 1,
|
||||
"uncertain": 0
|
||||
}
|
||||
},
|
||||
"results": [
|
||||
{
|
||||
"literatureId": "test-001",
|
||||
"title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.925,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "we randomly assigned 800 adults with type 2 diabetes",
|
||||
"I": "We evaluated the efficacy and safety of empagliflozin in patients with type 2 diabetes",
|
||||
"C": "placebo-controlled trial",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.9,
|
||||
"reason": "虽然该文献在PICO标准方面完全匹配（P：2型糖尿病成人患者；I：SGLT2抑制剂empagliflozin；C：安慰剂对照；S：随机对照试验），且满足纳入标准中的研究设计、干预措施、语言和时间要求，但文献明确缺乏心血管结局数据。摘要中仅报告了血糖控制（HbA1c变化）、体重、血压和不良事件等次要终点，未提及主要不良心血管事件、心衰住院或心血管死亡等心血管结局指标。根据研究方案要求，文献必须报告心血管结局数据才能纳入，因此予以排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes and inadequate glycemic control (HbA1c 7.0-10.0%)",
|
||||
"I": "to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily",
|
||||
"C": "placebo once daily",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "尽管该研究符合PICO中的P、I、C、S标准，人群为成人2型糖尿病患者，干预为SGLT2抑制剂（empagliflozin），对照为安慰剂，设计为RCT，但未报告方案所要求的心血管结局指标（如MACE、心衰住院、心血管死亡）。摘要中提及的结局为HbA1c、体重、血压和不良事件，无心血管相关终点数据，因此不满足纳入标准第4条“报告心血管结局数据”，故排除。"
|
||||
},
|
||||
"processingTime": 11935
|
||||
},
|
||||
{
|
||||
"literatureId": "test-002",
|
||||
"title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "include",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We randomly assigned 8246 patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
|
||||
"I": "ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor",
|
||||
"C": "ertugliflozin (5 mg or 15 mg) or placebo, in addition to standard care",
|
||||
"S": "We randomly assigned 8246 patients...The primary outcome was major adverse cardiovascular events"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者（≥18岁），干预措施为SGLT2抑制剂（ertugliflozin），对照为安慰剂加标准治疗，研究设计为随机对照试验，报告了心血管结局数据（主要不良心血管事件和心衰住院），发表于2010年后且为英文文献。同时，该文献未触发任何排除标准，不是综述、病例报告、动物实验、会议摘要或观察性研究。因此明确纳入。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
|
||||
"I": "ertugliflozin (5 mg or 15 mg)",
|
||||
"C": "placebo, in addition to standard care",
|
||||
"S": "We randomly assigned 8246 patients... to receive ertugliflozin (5 mg or 15 mg) or placebo"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入2型糖尿病成人患者，符合P标准；干预措施为SGLT2抑制剂ertugliflozin，符合I标准；对照为安慰剂，符合C标准；研究设计为随机对照试验，符合S标准。研究明确报告了主要不良心血管事件、心衰住院等结局，满足O维度要求。文献为英文RCT，发表于2010年后，非综述或观察性研究，完全符合所有纳入标准且未触发任何排除标准，因此决定纳入。"
|
||||
},
|
||||
"processingTime": 13225
|
||||
},
|
||||
{
|
||||
"literatureId": "test-003",
|
||||
"title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "in adults with type 2 diabetes",
|
||||
"I": "SGLT2 inhibitors",
|
||||
"C": "comparing SGLT2 inhibitors with placebo or active comparators",
|
||||
"S": "Systematic Review and Meta-Analysis"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "这篇文献明确触发排除标准第1条（综述、系统评价、Meta分析），因为标题和摘要都明确表明这是一篇系统综述和Meta分析，而非原始随机对照试验。虽然研究人群（2型糖尿病成人患者）、干预措施（SGLT2抑制剂）和对照（安慰剂或活性对照）都符合PICO标准，但研究设计类型不符合要求的RCT设计。根据排除标准，所有综述、系统评价和Meta分析都应被排除，因此直接排除此文献。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
|
||||
"I": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
|
||||
"C": "comparing SGLT2 inhibitors with placebo or active comparators",
|
||||
"S": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献为系统评价和Meta分析，研究设计不符合方案要求的原始随机对照试验（RCT），因此排除。尽管其纳入的研究可能符合PICO标准，但本文本身并非原始研究，不提供独立的实证数据。P、I、O均匹配或部分匹配，但S明确不匹配。根据排除标准第1条，系统评价和Meta分析应被排除。"
|
||||
},
|
||||
"processingTime": 10683
|
||||
},
|
||||
{
|
||||
"literatureId": "test-004",
|
||||
"title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection",
|
||||
"I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day)",
|
||||
"C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks",
|
||||
"S": "We investigated the effects of dapagliflozin on cardiac function in diabetic rats"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确不符合纳入标准，应予以排除。主要理由包括：(1)研究对象为糖尿病大鼠而非人类2型糖尿病患者，与PICO标准中'2型糖尿病成人患者'完全不匹配；(2)研究设计为动物实验而非随机对照试验，触发排除标准第3条；(3)虽然干预措施为SGLT2抑制剂(dapagliflozin)且设置了对照(vehicle)，但研究对象和研究设计的根本性不匹配决定了必须排除。这是一项基础医学研究，不符合系统综述关注临床证据的要求。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection.",
|
||||
"I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
|
||||
"C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
|
||||
"S": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究使用糖尿病大鼠模型，研究人群不符合成人2型糖尿病患者的要求，属于动物实验，明确违反纳入标准并触发排除标准3。尽管干预措施为dapagliflozin且采用随机设计，但研究对象非人类，无法外推至目标人群。研究设计虽提及随机分配，但整体为动物实验，不属于RCT临床试验。因此，该文献应排除。"
|
||||
},
|
||||
"processingTime": 13067
|
||||
},
|
||||
{
|
||||
"literatureId": "test-005",
|
||||
"title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
|
||||
"expectedDecision": "include",
|
||||
"actualDecision": "include",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
|
||||
"I": "receive canagliflozin at a dose of 100 mg daily",
|
||||
"C": "or placebo",
|
||||
"S": "In this double-blind trial, we randomly assigned 4401 participants"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者，干预措施为SGLT2抑制剂canagliflozin，对照为安慰剂，研究设计为随机对照试验。虽然摘要主要关注肾脏结局，但明确提到'cardiovascular events'作为复合终点的一部分，且'death from renal or cardiovascular causes'包含心血管死亡结局。研究发表于2010年后，为英文文献，完全符合所有PICO标准和纳入标准，无任何排除标准触发。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
|
||||
"I": "canagliflozin at a dose of 100 mg daily",
|
||||
"C": "placebo",
|
||||
"S": "In this double-blind trial, we randomly assigned 4401 participants...to receive canagliflozin...or placebo"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入2型糖尿病成人患者，使用SGLT2抑制剂（canagliflozin）作为干预，对照为安慰剂，研究设计为随机对照试验（RCT），符合PICO标准。摘要明确报告了心血管事件作为复合结局的一部分（'death from renal or cardiovascular causes'），满足心血管结局的纳入要求。研究发表于2018年（NEJM），英文全文，非综述或观察性研究，完全符合所有纳入标准且未触发任何排除标准，因此应纳入。"
|
||||
},
|
||||
"processingTime": 12352
|
||||
},
|
||||
{
|
||||
"literatureId": "test-006",
|
||||
"title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "\"12,543 adults with type 2 diabetes\"",
|
||||
"I": "\"patients with type 2 diabetes who initiated SGLT2 inhibitor therapy\"",
|
||||
"C": "摘要中未提及安慰剂或常规降糖疗法作为对照",
|
||||
"S": "\"We conducted a retrospective cohort study\""
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，应予以排除。虽然研究人群(P)为2型糖尿病成人患者，干预措施(I)为SGLT2抑制剂，符合纳入标准，但研究设计(S)为回顾性队列研究，明确不符合方案要求的随机对照试验(RCT)，且摘要中未提及任何对照措施(C)。此外，该研究主要关注血糖控制、体重变化和安全性结局，而非方案要求的心血管结局。根据排除标准第7条，观察性研究（包括队列研究）应被排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
|
||||
"I": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
|
||||
"C": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system.",
|
||||
"S": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究为回顾性队列研究，不符合方案要求的随机对照试验（RCT）设计，故S维度不匹配。虽然研究人群为成人2型糖尿病患者，且干预措施为SGLT2抑制剂，符合P和I标准，但对照组未明确为安慰剂或常规降糖疗法，C维度不匹配。此外，研究设计属于观察性研究，直接触发排除标准第7条，因此应排除。"
|
||||
},
|
||||
"processingTime": 11690
|
||||
},
|
||||
{
|
||||
"literatureId": "test-007",
|
||||
"title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "partial",
|
||||
"C": "match",
|
||||
"S": "partial"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers",
|
||||
"I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner",
|
||||
"C": "placebo-controlled",
|
||||
"S": "In this Phase 1 study...in a randomized, placebo-controlled, double-blind manner"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献应被排除，主要原因为：研究人群明确为健康志愿者而非2型糖尿病患者（P不匹配），这直接违反了纳入标准第1条和排除标准第5条。虽然研究涉及SGLT2抑制剂empagliflozin（I部分匹配）并采用安慰剂对照（C匹配），但研究设计为I期临床试验而非典型的RCT（S部分匹配），且未报告任何心血管结局数据。此外，研究关注的是药代动力学和药效学参数，与研究方案要求的心血管结局完全不符。基于研究人群不符合PICO标准且触发排除标准，决定排除该文献。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "mismatch",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers.",
|
||||
"I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
|
||||
"C": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
|
||||
"S": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入的是健康志愿者，而非2型糖尿病患者，不符合P（研究人群）标准。尽管研究设计为RCT，干预措施为SGLT2抑制剂，对照为安慰剂，且发表于英文期刊，但P的不匹配直接触发排除标准第5条（健康志愿者研究）。因此，尽管其他PICO要素部分符合，仍应排除。"
|
||||
},
|
||||
"processingTime": 14253
|
||||
},
|
||||
{
|
||||
"literatureId": "test-008",
|
||||
"title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "partial",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "Medicare beneficiaries aged ≥65 years with type 2 diabetes",
|
||||
"I": "patients initiating SGLT2 inhibitors (n=42,371)",
|
||||
"C": "compared with those initiating DPP-4 inhibitors (n=126,806)",
|
||||
"S": "We conducted a nationwide cohort study using claims data"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，主要问题在于研究设计不符合要求。文献明确描述为队列研究（nationwide cohort study using claims data），而研究方案要求必须是随机对照试验（RCT）。对照措施部分匹配，虽然使用了DPP-4抑制剂作为对照，但研究方案要求安慰剂或常规降糖疗法。研究人群（老年2型糖尿病患者）和干预措施（SGLT2抑制剂）符合要求，结局指标也报告了心血管结局（心衰住院、主要不良心血管事件）。但由于研究设计为观察性队列研究，明确触发排除标准第7条，因此必须排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries aged ≥65 years with type 2 diabetes.",
|
||||
"I": "We compared patients initiating SGLT2 inhibitors (n=42,371) with those initiating DPP-4 inhibitors (n=126,806) between 2013 and 2017.",
|
||||
"C": "those initiating DPP-4 inhibitors",
|
||||
"S": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入的是2型糖尿病患者，符合P标准；干预措施为SGLT2抑制剂，符合I标准。但对照组为DPP-4抑制剂，不符合方案中‘安慰剂或常规降糖疗法’的C标准，属于非等效对照。更重要的是，研究设计为队列研究，属于观察性研究，不满足S要求的随机对照试验（RCT），明确触发排除标准中的‘观察性研究’条款。因此，尽管部分PICO要素匹配，但因研究设计不符，应排除。"
|
||||
},
|
||||
"processingTime": 12808
|
||||
},
|
||||
{
|
||||
"literatureId": "test-009",
|
||||
"title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
|
||||
"expectedDecision": "exclude",
|
||||
"actualDecision": "exclude",
|
||||
"isCorrect": true,
|
||||
"hasConsensus": true,
|
||||
"needReview": false,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "\"A 52-year-old man with type 2 diabetes\"",
|
||||
"I": "\"patient treated with dapagliflozin\"",
|
||||
"C": "摘要中未提及任何对照措施或安慰剂",
|
||||
"S": "\"We report a case of severe euglycemic diabetic ketoacidosis\"，明确为病例报告"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准：这是一篇病例报告（标题和摘要中多次提及'case report'和'case'），而非随机对照试验。虽然研究人群（2型糖尿病患者）和干预措施（SGLT2抑制剂）符合PICO标准，但研究设计不符合要求的RCT设计，且未报告心血管结局数据（主要讨论糖尿病酮症酸中毒）。根据排除标准第2条（病例报告、病例系列），应直接排除。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "mismatch",
|
||||
"S": "mismatch"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
|
||||
"I": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
|
||||
"C": "There is no mention of a control group or comparison with placebo or conventional therapy.",
|
||||
"S": "This is a case report, as indicated by the title: 'Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report'."
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献为病例报告，研究设计不符合方案要求的随机对照试验（RCT），故S维度不匹配。尽管研究人群（P）和干预措施（I）符合标准，但缺乏对照组（C），且研究类型属于排除标准中的'病例报告'。根据排除标准第2条，此类文献应被排除。虽然提到了2型糖尿病患者使用SGLT2抑制剂，但无对照、非RCT设计，无法提供因果推断证据，因此最终决定排除。"
|
||||
},
|
||||
"processingTime": 12092
|
||||
},
|
||||
{
|
||||
"literatureId": "test-010",
|
||||
"title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
|
||||
"expectedDecision": "uncertain",
|
||||
"actualDecision": "pending",
|
||||
"isCorrect": false,
|
||||
"hasConsensus": false,
|
||||
"needReview": true,
|
||||
"avgConfidence": 0.95,
|
||||
"deepseekResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "mismatch",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "we enrolled 10,584 patients with type 2 diabetes",
|
||||
"I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
|
||||
"C": "randomly assigned to receive sotagliflozin 200 mg or placebo",
|
||||
"S": "In this randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "exclude",
|
||||
"confidence": 0.95,
|
||||
"reason": "该文献明确触发排除标准，主要问题在于干预措施不匹配。研究使用的是sotagliflozin（一种SGLT1和SGLT2双重抑制剂），而非方案要求的SGLT2抑制剂（如empagliflozin、dapagliflozin、canagliflozin等）。虽然研究人群（2型糖尿病成人患者）、对照（安慰剂）、研究设计（RCT）和结局指标（心血管结局）均符合PICO标准，且满足纳入标准中的研究设计、结局报告、语言和发表时间要求，但干预措施的根本性差异导致必须排除。SGLT1/SGLT2双重抑制剂与纯SGLT2抑制剂在作用机制和临床效果上存在差异，不应混为一谈。"
|
||||
},
|
||||
"qwenResult": {
|
||||
"judgment": {
|
||||
"P": "match",
|
||||
"I": "match",
|
||||
"C": "match",
|
||||
"S": "match"
|
||||
},
|
||||
"evidence": {
|
||||
"P": "patients with type 2 diabetes, cardiovascular disease, and an estimated glomerular filtration rate of 25 to 60 ml per minute per 1.73 m²",
|
||||
"I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor... patients were randomly assigned to receive sotagliflozin 200 mg or placebo once daily",
|
||||
"C": "placebo once daily",
|
||||
"S": "randomized, double-blind, placebo-controlled trial"
|
||||
},
|
||||
"conclusion": "include",
|
||||
"confidence": 0.95,
|
||||
"reason": "该研究纳入2型糖尿病成人患者，符合P标准；干预措施为SGLT2抑制剂（sotagliflozin），虽为双抑制剂但包含SGLT2抑制作用，符合I标准；对照为安慰剂，符合C标准；研究设计为RCT，符合S标准。心血管结局明确报告了心血管死亡、心衰住院等复合终点，满足O指标要求。研究发表于2019年（基于背景知识），英文全文，非排除类型，完全符合所有纳入标准且未触发任何排除标准。"
|
||||
},
|
||||
"processingTime": 13503
|
||||
}
|
||||
]
|
||||
}
|
||||
Reference in New Issue
Block a user